title: Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies.
abstract: BACKGROUND
  Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.
  
  
  METHODS
  Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.
  
  
  CONCLUSIONS
  The purpose of this review is to summarize the "state of art" of current novel therapeutic strategies to stem this debilitating kidney disease.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Pofi
authors.forename: Francesca
authors.initials: F
authors.lastname: Di Mario
authors.forename: Antonietta
authors.initials: A
authors.lastname: Gigante
authors.forename: Edoardo
authors.initials: E
authors.lastname: Rosato
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Isidori
authors.forename: Antonio
authors.initials: A
authors.lastname: Amoroso
authors.forename: Rosario
authors.initials: R
authors.lastname: Cianci
authors.affiliation: Department of Clinical Medicine, Sapienza University of Rome,Viale del Policlinico 15500161 - Rome - Italy. biagionet@hotmail.com.
authors.forename: Biagio
authors.initials: B
authors.lastname: Barbano
mesh_terms: D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents